Search alternatives:
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
w decrease » we decrease (Expand Search), _ decrease (Expand Search), _ decreased (Expand Search)
Showing 321 - 340 results of 64,280 for search '(( 5 ((nn decrease) OR (a decrease)) ) OR ( 5 ((w decrease) OR (teer decrease)) ))', query time: 0.91s Refine Results
  1. 321
    Data_Sheet_3_The German Quality Network Sepsis: Evaluation of a Quality Collaborative on Decreasing Sepsis-Related Mortality in a Controlled Interrupted Time Series Analysis.pdf

    Data_Sheet_3_The German Quality Network Sepsis: Evaluation of a Quality Collaborative on Decreasing Sepsis-Related Mortality in a Controlled Interrupted Time Series Analysis.pdf by Daniel Schwarzkopf (4984601)

    Published 2022
    “…This study presents the evaluation of a quality collaborative, which aimed to decrease sepsis-related hospital mortality.…”
    Save to List
    Saved in:
  2. 322
    Data_Sheet_1_The German Quality Network Sepsis: Evaluation of a Quality Collaborative on Decreasing Sepsis-Related Mortality in a Controlled Interrupted Time Series Analysis.pdf

    Data_Sheet_1_The German Quality Network Sepsis: Evaluation of a Quality Collaborative on Decreasing Sepsis-Related Mortality in a Controlled Interrupted Time Series Analysis.pdf by Daniel Schwarzkopf (4984601)

    Published 2022
    “…This study presents the evaluation of a quality collaborative, which aimed to decrease sepsis-related hospital mortality.…”
    Save to List
    Saved in:
  3. 323
    Data_Sheet_2_The German Quality Network Sepsis: Evaluation of a Quality Collaborative on Decreasing Sepsis-Related Mortality in a Controlled Interrupted Time Series Analysis.pdf

    Data_Sheet_2_The German Quality Network Sepsis: Evaluation of a Quality Collaborative on Decreasing Sepsis-Related Mortality in a Controlled Interrupted Time Series Analysis.pdf by Daniel Schwarzkopf (4984601)

    Published 2022
    “…This study presents the evaluation of a quality collaborative, which aimed to decrease sepsis-related hospital mortality.…”
    Save to List
    Saved in:
  4. 324
    Amplitude for A/L = 0.29.

    Amplitude for A/L = 0.29. by Muhammad Hammad Bucha (21736111)

    Published 2025
    “…The smoothest cylinder (K<sub>s</sub>/D = ) produced the highest power (52.325 µW), while the roughest (K<sub>s</sub>/D = ) resulted in a 6.26% decrease in power (36.4 µW), along with reductions of 4.5% in flapping frequency and 20% in amplitude. …”
    Save to List
    Saved in:
  5. 325
    Amplitude for A/L = 0.338.

    Amplitude for A/L = 0.338. by Muhammad Hammad Bucha (21736111)

    Published 2025
    “…The smoothest cylinder (K<sub>s</sub>/D = ) produced the highest power (52.325 µW), while the roughest (K<sub>s</sub>/D = ) resulted in a 6.26% decrease in power (36.4 µW), along with reductions of 4.5% in flapping frequency and 20% in amplitude. …”
    Save to List
    Saved in:
  6. 326
    Amplitude for A/L = 0.02.

    Amplitude for A/L = 0.02. by Muhammad Hammad Bucha (21736111)

    Published 2025
    “…The smoothest cylinder (K<sub>s</sub>/D = ) produced the highest power (52.325 µW), while the roughest (K<sub>s</sub>/D = ) resulted in a 6.26% decrease in power (36.4 µW), along with reductions of 4.5% in flapping frequency and 20% in amplitude. …”
    Save to List
    Saved in:
  7. 327
    Amplitude for A/L = 0.03.

    Amplitude for A/L = 0.03. by Muhammad Hammad Bucha (21736111)

    Published 2025
    “…The smoothest cylinder (K<sub>s</sub>/D = ) produced the highest power (52.325 µW), while the roughest (K<sub>s</sub>/D = ) resulted in a 6.26% decrease in power (36.4 µW), along with reductions of 4.5% in flapping frequency and 20% in amplitude. …”
    Save to List
    Saved in:
  8. 328
    Supplemental Figure 1 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume

    Supplemental Figure 1 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume by Nicholas Theodosakis (3466673)

    Published 2023
    Save to List
    Saved in:
  9. 329
    Supplemental Figure 7 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume

    Supplemental Figure 7 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume by Nicholas Theodosakis (3466673)

    Published 2023
    Save to List
    Saved in:
  10. 330
    Supplemental Figure 2 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume

    Supplemental Figure 2 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume by Nicholas Theodosakis (3466673)

    Published 2023
    Save to List
    Saved in:
  11. 331
    Supplemental Table 1 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume

    Supplemental Table 1 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume by Nicholas Theodosakis (3466673)

    Published 2023
    Save to List
    Saved in:
  12. 332
    Supplemental Figure 6 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume

    Supplemental Figure 6 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume by Nicholas Theodosakis (3466673)

    Published 2023
    Save to List
    Saved in:
  13. 333
    Supplemental Figure 4 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume

    Supplemental Figure 4 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume by Nicholas Theodosakis (3466673)

    Published 2023
    Save to List
    Saved in:
  14. 334
    Supplemental Figure 8 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume

    Supplemental Figure 8 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume by Nicholas Theodosakis (3466673)

    Published 2023
    Save to List
    Saved in:
  15. 335
    Supplemental Figure 3 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume

    Supplemental Figure 3 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume by Nicholas Theodosakis (3466673)

    Published 2023
    Save to List
    Saved in:
  16. 336
    Supplemental Figure 9 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume

    Supplemental Figure 9 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume by Nicholas Theodosakis (3466673)

    Published 2023
    Save to List
    Saved in:
  17. 337
    Proposed treatment algorithm for 5-FU (Fluorouracil) coronary vasospasm patients.

    Proposed treatment algorithm for 5-FU (Fluorouracil) coronary vasospasm patients. by Amna Zafar (12369151)

    Published 2022
    Save to List
    Saved in:
  18. 338
    Schematic presentation <i>M</i>. <i>bovis</i> PG45 5′ nucleotidase and phylogenetic tree of its homologs.

    Schematic presentation <i>M</i>. <i>bovis</i> PG45 5′ nucleotidase and phylogenetic tree of its homologs. by Aga E. Gelgie (17661720)

    Published 2024
    Save to List
    Saved in:
  19. 339
    Latent growth curve model estimating the change in moderate-to-vigorous physical activity (MVPA) from follow-up surveys W1 to W3.

    Latent growth curve model estimating the change in moderate-to-vigorous physical activity (MVPA) from follow-up surveys W1 to W3. by Glen E. Duncan (9238792)

    Published 2021
    Save to List
    Saved in:
  20. 340
    Baseline characteristics of all patients with vasospasm, and comparison of those of who continued 5-FU therapy with cardiac pre-treatment vs. those who stopped 5-FU therapy.

    Baseline characteristics of all patients with vasospasm, and comparison of those of who continued 5-FU therapy with cardiac pre-treatment vs. those who stopped 5-FU therapy. by Amna Zafar (12369151)

    Published 2022
    Save to List
    Saved in:

Search Tools: